Last reviewed · How we verify
NCT05887297
Impact of Cognitive Behavioural Therapy for Insomnia on Endocrine Therapy Adherence
NA trial testing Cognitive behavioural therapy for insomnia in Insomnia in 35 participants. Completed in 23 April 2024.
23 April 2024
Quick facts
| Lead sponsor | University of Strathclyde |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 35 |
| Start date | 23 March 2023 |
| Primary completion | 23 April 2024 |
| Estimated completion | 23 April 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Cognitive behavioural therapy for insomnia
Conditions studied
- Insomnia — all drugs for Insomnia →
- Breast Cancer — all drugs for Breast Cancer →
- Adherence, Medication — all drugs for Adherence, Medication →
- Quality of Life — all drugs for Quality of Life →
Sponsor
University of Strathclyde
Who can join
18 and older, any sex, with Insomnia or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate the impact of cognitive behavioural therapy for insomnia on adherence to endocrine therapy medication in breast cancer survivors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05887297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cognitive behavioural therapy for insomnia
Trials testing the same drug.
- NCT04653155 — Cognitive Behavioural Therapy for Insomnia for Chinese Adults: a RCT · NA · unknown
- NCT03736694 — Low-intensity Cognitive-behavioural Therapy for Insomnia · NA · completed
Other recruiting trials for Insomnia
Currently open trials in the same condition.
- NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
- NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting
- NCT07071324 — CF Wellness Program · NA · recruiting
- NCT07417813 — A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders · recruiting
- NCT06348082 — Project Women's Insomnia Sleep Health Equity Study (WISHES) · NA · recruiting
Other University of Strathclyde trials
Trials by the same sponsor.
- NCT06806748 — Gait Recovery After Stroke · not yet recruiting
- NCT06928285 — Community Rollout of Technology Enriched Rehabilitation After Stroke: An Implementation Study · NA · not yet recruiting
- NCT06894953 — AMPER Proof of Concept Study · NA · not yet recruiting
- NCT06419062 — The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 2 · enrolling by invitation
- NCT06419036 — The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05887297 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Strathclyde
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05887297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing